Fulminant Myocarditis with Combination Immune Checkpoint BlockadeDouglas B. Johnson, Javid J. Moslehi, Justin M. Balko et al.|New England Journal of Medicine|2016Cited by 2.3k
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 BlockadeDouglas B. Johnson, Christine M. Lovly, Riley Ennis et al.|Cancer Immunology Research|2016Cited by 493
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancerDaniel G. Stover, Nancy U. Lin, Carlos R. Gil Del Alcazar et al.|npj Breast Cancer|2018Cited by 150